Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 3/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2919185 | 0.90 | STAT3 (0.49) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL2925163 | 0.89 | STAT3 (0.48) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL2924480 | 0.87 | CYP2C9 (0.51) | CYP3A4CYP2C9KDM4EHPGDHTT | |
| SCHEMBL7008770 | 0.87 | STAT3 (0.47) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL10018778 | 0.85 | CYP3A4 (0.56) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL7172797 | 0.84 | STAT3 (0.50) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL2919782 | 0.83 | STAT3 (0.51) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL2916260 | 0.83 | STAT3 (0.47) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL7171539 | 0.82 | STAT3 (0.42) | STAT3CYP3A4CYP2C9KDM4EHPGD | |
| SCHEMBL2918965 | 0.82 | STAT3 (0.50) | STAT3CYP3A4CYP2C9KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813610-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMA CO LTD (JP) | 2010-09-08 | — | — | EP | disclosed |
| US-7713997-B2 | Pyridonecarboxylic acid derivatives or salts thereof | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2010-05-11 | — | — | US | disclosed |
| US-20090149440-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD (JP) | 2009-06-11 | — | — | US | disclosed |
| EP-1813610-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-01 | — | — | EP | disclosed |
| EP-0952151-B1 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMA CO LTD (JP) | 2003-05-28 | — | — | EP | disclosed |
| EP-0911327-B1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMA CO LTD (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6156903-A | Pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6133284-A | EXCELLENT BACTERICIDAL PROPERTIES AND ORAL ABSORPTION; INFECTIONS FROM GRAMNEGATIVE AND -POSITIVE BACTERIA; INTESTINAL ABSORPTION, METABOLIC STABILITY; SIDE EFFECT REDUCTION; NONPHOTOTOXICITY AND NONCYTOTOXICITY | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-17 | — | — | US | disclosed |
| EP-0992501-A2 | Pyridonecarboxylic acid derivatives as antibacterial agents | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | disclosed |
| US-5998436-A | Pyridonecarboxylic acid derivatives or their salts and antibacterial agent comprising the same as the active ingredient | WAKUNAGA PHARMACEUTICALS CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0952151-A2 | Intermediates for use in preparing novel pyridonecarboxylic acid derivatives or their salts | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-10-27 | — | — | EP | disclosed |
| EP-0911327-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR THEIR SALTS AND ANTIBACTERIAL AGENT COMPRISING THE SAME AS THE ACTIVE INGREDIENT | WAKUNAGA PHARMACEUTICAL CO., LTD. (JP) | 1999-04-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149440-A1 | NOVEL PYRIDONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | SLC7A1, PLPBP, PYCR1 | STAT3 593/4885CYP3A4 863/4885CYP2C9 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.